Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Primary cutaneous indolent B-cell lymphomas - a retrospective multicenter analysis and a review of literature.
Olszewska-Szopa M, Sobas M, Laribi K, Bao Perez L, Drozd-Sokołowska J, Subocz E, Joks M, Zduniak K, Gajewska M, de Nalecz AK, Romejko-Jarosińska J, Kumiega B, Waszczuk-Gajda A, Wróbel T, Czyz A. Olszewska-Szopa M, et al. Among authors: laribi k. Acta Oncol. 2021 Oct;60(10):1361-1368. doi: 10.1080/0284186X.2021.1956689. Epub 2021 Aug 4. Acta Oncol. 2021. PMID: 34346830 Review.
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.
Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, Roussel M, Montes L, Cherel B, Chalopin T, Slama B, Chretien ML, Laribi K, Dingremont C, Roul C, Mariette C, Rigaudeau S, Calmettes C, Dib M, Tiab M, Vincent L, Delaunay J, Santagostino A, Macro M, Bourgeois E, Orsini-Piocelle F, Gay J, Bareau B, Bigot N, Vergez F, Lebreton P, Tabrizi R, Waultier-Rascalou A, Frenzel L, Le Calloch R, Chalayer E, Braun T, Lachenal F, Corm S, Kennel C, Belkhir R, Bladé JS, Joly B, Richez-Olivier V, Gardeney H, Demarquette H, Robu-Cretu D, Garderet L, Newinger-Porte M, Kasmi A, Royer B, Decaux O, Arnulf B, Belhadj K, Touzeau C, Mohty M, Manier S, Moreau P, Avet-Loiseau H, Corre J, Facon T. Leleu X, et al. Among authors: laribi k. Nat Med. 2024 Aug;30(8):2235-2241. doi: 10.1038/s41591-024-03050-2. Epub 2024 Jun 3. Nat Med. 2024. PMID: 38830994 Free PMC article. Clinical Trial.
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study.
Macro M, Hulin C, Vincent L, Charvet-Rumpler A, Benboubker L, Calmettes C, Stoppa AM, Laribi K, Clement-Filliatre L, Zerazhi H, Honeyman F, Richez V, Maloisel F, Karlin L, Barrak J, Chouaid C, Leleu X. Macro M, et al. Among authors: laribi k. Ann Hematol. 2023 Aug;102(8):2137-2151. doi: 10.1007/s00277-023-05278-3. Epub 2023 Jun 10. Ann Hematol. 2023. PMID: 37301786 Free PMC article.
Fatigue visual analogue scale score correlates with quality of life in cancer patients receiving epoetin alfa (Sandoz) for chemotherapy-induced anaemia: The CIROCO study.
Desramé J, Baize N, Anota A, Laribi K, Stefani L, Hjiej S, Nabirotchkina E, Zelek L, Choquet S. Desramé J, et al. Among authors: laribi k. Cancer Treat Res Commun. 2023;37:100781. doi: 10.1016/j.ctarc.2023.100781. Epub 2023 Nov 23. Cancer Treat Res Commun. 2023. PMID: 38039763 Free article.
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team. Benboubker L, et al. N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551. N Engl J Med. 2014. PMID: 25184863 Free article. Clinical Trial.
Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms.
Denizon N, Baugier de Materre A, Alani M, Ghnaya H, Farhi J, Besançon A, Laribi K. Denizon N, et al. Among authors: laribi k. Leuk Lymphoma. 2018 Nov;59(11):2711-2714. doi: 10.1080/10428194.2018.1452214. Epub 2018 Mar 21. Leuk Lymphoma. 2018. PMID: 29561205 No abstract available.
Recent Advances in the Treatment of Peripheral T-Cell Lymphoma.
Laribi K, Alani M, Truong C, Baugier de Materre A. Laribi K, et al. Oncologist. 2018 Sep;23(9):1039-1053. doi: 10.1634/theoncologist.2017-0524. Epub 2018 Apr 19. Oncologist. 2018. PMID: 29674443 Free PMC article. Review.
Lymphomas with kidney involvement: the French multicenter retrospective LyKID study.
Kohn M, Karras A, Zaidan M, Bénière C, de Fréminville JB, Laribi K, Perrin MC, Malphettes M, Le Calloch R, Anglaret B, Martiniuc J, Bailly S, Chevret S, Molina T, Thervet E, Thieblemont C. Kohn M, et al. Among authors: laribi k. Leuk Lymphoma. 2020 Apr;61(4):887-895. doi: 10.1080/10428194.2019.1697811. Epub 2020 Feb 10. Leuk Lymphoma. 2020. PMID: 32037948
128 results